Manipal Hospitals
| India | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $3,200 | from $7,000 | from $12,000 |
| Radiation Therapy for Sarcomas | from $4,500 | from $3,250 | from $18,000 |
| Proton-beam therapy | from $25,000 | from $70,000 | from $80,000 |
| Proton therapy for prostate cancer | from $35,000 | from $30,000 | from $80,000 |
| Proton therapy for breast cancer | from $26,000 | from $30,000 | from $55,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Leiomyosarkoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Leiomyosarkoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Leiomyosarkoma treatment journey.
Dr. Shruti Kate specializes in treating advanced cancers with immunotherapy and metronomic therapy, with research presented at the World Conference on Lung Cancer.
Performed 50,000+ cancer surgeries over 30 years of experience – Dr. Raj specializes in breast and thoracic surgical oncology.
Handled more than 30,000 PET scans and 1,000 thyroid cancer patients – Dr. Borde specializes in nuclear medicine at HCG Manavata Cancer Centre.
Surgery is the primary treatment for Leiomyosarcoma in India. Surgeons perform radical resection to achieve clear margins. Specialized centers combine surgery with radiation or chemotherapy. Treatment follows National Cancer Grid standards. Multidisciplinary teams manage complex cases to ensure local control and prevent spread.
Bookimed Expert Insight: India offers a high density of oncology expertise across specialized hubs like Chennai and Gurgaon. Clinics like Global Hospital Chennai and Dr. Rela Institute often utilize linear accelerators with 1 mm accuracy for tumor irradiation. This precision is vital for Leiomyosarcoma near critical organs. Patients should look for NABH-accredited facilities to ensure these technology standards are met.
Patient Consensus: Patients note that surgery is the first step whenever the tumor is removable. Many emphasize the need to confirm that pathology and imaging resources are available on-site for faster results.
Major Indian oncology centers provide both genomic and hormone receptor testing for Leiomyosarcoma. Facilities use Next-Generation Sequencing to identify mutations in rare soft tissue sarcomas. Immunohistochemistry is standard for checking hormone receptor status. These diagnostics guide personalized treatment and target specific molecular alterations.
Bookimed Expert Insight: Indian hospitals like HCG Manavata use IBM Watson to help select cancer treatments. This combines local clinical data with global research to interpret complex genomic profiling. This technology bridges the gap between raw testing data and clear treatment steps. It is especially useful for rare conditions like Leiomyosarcoma where standard protocols often change.
Patient Consensus: Patients note that pathology quality remains the most critical factor. They recommend verifying the original diagnosis with a specialized sarcoma pathologist before starting expensive molecular testing.
India offers immunotherapy and clinical trials for leiomyosarcoma through specialized oncology centers. These treatments are often available at institutions like HCG Manavata Cancer Centre and Medanta Hospital. Participation in research trials is common for advanced cases that do not respond to standard surgery or radiation.
Bookimed Expert Insight: Patient volume is a major indicator of clinical trial access in India. HCG Manavata Cancer Centre serves over 100,000 patients globally. Its lead surgeon, Dr. Raj Nagarkar, has performed over 50,000 surgeries and led complex phase 1-3 trials. Choosing centers with high surgical volumes often provides more robust infrastructure for emerging therapies like immunotherapy.
Patient Consensus: Patients emphasize the need to ask directly about active recruitment for leiomyosarcoma rather than general sarcomas. They note that bringing full pathology reports is essential for biomarker-driven trial eligibility.
Patients should seek care at high-volume oncology centers in Bengaluru, Gurgaon, and Chennai for leiomyosarcoma. Specialized facilities like Manipal Hospitals and Medanta Hospital provide multidisciplinary tumor boards. These institutions utilize advanced imaging and precise surgical resection. Integrated care focuses on preventing recurrence through wide-margin oncology surgery.
Bookimed Expert Insight: A clear pattern emerges among India's top cancer centers: they centralize expertise from premier public institutions. For example, key specialists at HCG Manavata Cancer Centre, including Dr. Shruti Kate and Prof. Dr. Raj Nagarkar, completed their advanced training at Tata Memorial Hospital. Choosing a private center often grants faster access to this specific high-volume expertise alongside advanced technologies like the Da Vinci robotic system.
Patient Consensus: Patients note it is important to choose a facility where the surgical leads have specific sarcoma training rather than general surgery backgrounds. Many emphasize that having PET-CT and advanced imaging on-site speeds up the treatment planning significantly.
India maintains a robust network of dedicated sarcoma specialists focused on bone and soft-tissue tumors. These experts operate within multidisciplinary teams at major oncology hubs. Centers like HCG Manavata and Global Hospital utilize JCI-accredited facilities to provide specialized leiomyosarcoma care and advanced surgical interventions.
Bookimed Expert Insight: While general oncology is available nationwide, the highest concentration of sarcoma expertise remains in Bengaluru, Chennai, and Mumbai. For example, Global Hospital Chennai and Manipal Hospitals serve over 80,000 and 2,000,000 patients annually. This high volume allows surgeons to maintain specialized skills in rare tumor resections that smaller facilities may not encounter frequently.
Patient Consensus: Patients note it is essential to seek a second pathology review because sarcoma subtypes are often misclassified. Many emphasize that traveling to high-volume centers in major cities significantly improves the quality of the treatment plan.
Leiomyosarcoma treatment in India requires between 14 days and 4 months depending on the medical approach. Localized surgery usually necessitates 10 to 14 days for recovery. Complex systemic therapies like multi-cycle chemotherapy or daily radiation protocols extend the necessary stay to several months.
Bookimed Expert Insight: Indian oncology centers like HCG Manavata and Fortis Gurgaon utilize high-precision diagnostics that can shorten the pre-surgical phase. Dr. Raj Nagarkar has performed over 50,000 procedures, emphasizing that expert surgical speed often reduces initial hospital stays. However, advanced LMS cases may involve retroperitoneal surgery, which typically requires a more cautious 2-week inpatient observation period.
Patient Consensus: Patients emphasize the need for flexible return flights since post-operative wound checks or drain removals often change original timelines. It is widely recommended to bring specialized pathology slides from home to prevent diagnostic delays upon arrival.
Indian hospitals typically accept foreign pathology slides for review. Major institutions like Manipal Hospitals and Fortis Gurgaon require internal verification before starting leiomyosarcoma treatment. Local pathologists must re-examine tissue blocks to confirm tumor margins and grading. This step ensures diagnostic accuracy and protocol alignment.
Bookimed Expert Insight: Our data shows a high preference for major cancer centers like HCG Manavata for rare conditions. Dr. Raj Nagarkar there has performed over 50,000 surgeries. This massive volume means pathology departments at such centers are experts at identifying subtle leiomyosarcoma subtypes. Choosing a facility that handles over 75,000 patients yearly often lead to faster slide review cycles.
Patient Consensus: Patients note it's important to bring actual tissue blocks, not just paper reports. Many found that internal reviews confirmed the diagnosis but refined the treatment plan for better outcomes.
Leiomyosarcoma treatment in India focuses on surgical resection with clean margins as the primary curative path. Specialised multidisciplinary teams use technologies such as CyberKnife, Da Vinci robotic surgery, and Proton Beam therapy. These treat tumours in complex locations while sparing healthy tissue.
Bookimed Expert Insight: Indian oncology centres often provide access to highly specialised equipment like the 4D radiotherapy found at Dr Rela Institute. This technology is essential for leiomyosarcomas located near moving organs. While many global centres treat general cancers, HCG Manavata Cancer Centre has treated over 25,000 radiotherapy patients. This offers deep experience in rare soft tissue tumours.
Patient Consensus: Patients in India highlight that surgery must be performed by dedicated sarcoma specialists to prevent spread. They note that doxorubicin-based chemotherapy regimens and post-operative radiation are standard practices for managing recurrence risks.
India houses highly skilled surgical and medical oncologists specialising in leiomyosarcoma at accredited cancer centres. Top specialists include Dr Raj Nagarkar and Dr Shruti Kate at HCG Manavata Cancer Centre. These doctors work within multidisciplinary teams to provide surgery, chemotherapy, and radiation.
Bookimed Expert Insight: Dr Raj Nagarkar holds MRCS credentials from Edinburgh. This qualification is widely recognised by Australian medical boards. This makes him a suitable choice for Australian patients. Furthermore, HCG Manavata is the region’s first centre to offer TomoTherapy-H. This technology provides the precise radiation required for complex leiomyosarcoma cases.
Patient Consensus: Patients note that standard leiomyosarcoma care in India involves chemotherapy and surgery. Experts recommend having a vascular surgeon present if tumours involve blood vessels.
Targeted therapy and immunotherapy are available for leiomyosarcoma in India at major oncology centres. Specialists combine targeted agents like pazopanib and trabectedin with immunotherapy. This is used for cases where chemotherapy is ineffective. Treatment is delivered through JCI-accredited facilities using technologies like CyberKnife and TomoTherapy-H.
Bookimed Expert Insight: India ranks top 10 globally for complex oncology requests on Bookimed. Centres like HCG Manavata stand out by combining surgical volume with US-FDA audited research. This allows patients to access phase 1–3 clinical trials for refractory leiomyosarcoma. These trials are not yet standard treatments elsewhere.
Patient Consensus: Patients in India find that treatment for leiomyosarcoma is highly individualised. It is based on molecular markers. Experts advise patients to confirm the availability of specific tyrosine kinase inhibitors. This should be done at the chosen hospital before travel.
Private Indian hospitals offer immediate treatment for leiomyosarcoma. Diagnostics often start within 24 to 48 hours of arrival. While public facilities face longer delays, major private centres provide rapid access to therapies. Specialist consultation, staging scans, and surgery typically proceed without delays. This means patients avoid the months-long waiting lists found elsewhere.
Bookimed Expert Insight: Public hospitals struggle with volume. However, private Indian hospitals operate at massive scale to eliminate queues. Major centres like Manipal Hospitals serve over 2,000,000 patients annually. This high capacity allows them to absorb international cases immediately. This is critical for leiomyosarcoma. Delays in diagnosis can allow the cancer to spread.
Patient Consensus: Patients note that chemotherapy cycles need 2–3 week gaps for recovery. However, the initial treatment start is fast. They emphasise choosing specialised sarcoma centres in India. This avoids diagnostic delays found in other healthcare systems.
Patients can access leiomyosarcoma clinical trials in India. They can search through the Clinical Trials Registry - India (CTRI) or international databases. Specialised oncology centres like HCG Manavata Cancer Centre and Tata Memorial Hospital lead research for rare sarcomas. These facilities often conduct Phase 1–3 trials for advanced cases.
Bookimed Expert Insight: Clinical trial access in India often concentrates in centres with US-FDA-audited research wings. HCG Manavata Cancer Centre serves 75,000 patients annually and manages over 200 trials. Patients should target these high-volume facilities. They often secure international trial sites for rare smooth-muscle cancers.
Patient Consensus: Patients note it is essential to consult an oncologist about international trial networks. Many find real-time updates through sarcoma-specific support groups. They cross-reference global registries for Indian sites.